Ivabradine (Procoralan) Summary of therapeutic value

For patients who have stable angina pectoris and do not tolerate ßblockers or have a contraindication to ß-blockers, ivabradine monotherapy has a
therapeutic added value for a limited sub-group of patients, i.e., those who do not benefit from a calcium antagonist or a long-working nitrate. For patients with stable angina pectoris in whom ß-blockers are insufficiently effective, the addition of ivabradine (combination therapy) has – because of a lack of clinical research data and limited efficacy in placebo-controlled research – a lower therapeutic value than the standard treatment, which is comprised of adding a dihydropyridine calcium antagonist or a long-working nitrate.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.